Investing.com - Jefferies reiterated a Buy rating and $230.00 price target on Insmed (NASDAQ:INSM) shares following positive trial data from a competitor in the inhaled prostacyclin class. The stock ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results